Related references
Note: Only part of the references are listed.Cardioprotection conferred by sodium-glucose cotransporter 2 inhibitors: a renal proximal tubule perspective
Danubia Silva dos Santos et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2020)
The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial
Erik J. M. van Bommel et al.
KIDNEY INTERNATIONAL (2020)
Therapeutic Effects of SGLT2 Inhibitor Ipragliflozin and Metformin on NASH in Type 2 Diabetic Mice
Atsuo Tahara et al.
ENDOCRINE RESEARCH (2020)
Inter-organ Communication Pathway Manifested by Non-physiological Stress to the Kidney in Type II Diabetic Patients -Why Are Diabetic Patients Prone to Develop Heart Failure?
Motoaki Sano
INTERNAL MEDICINE (2020)
Do sodium-glucose cotransporter-2 inhibitors affect renal hemodynamics by different mechanisms in type 1 and type 2 diabetes?
Petter Bjornstad et al.
KIDNEY INTERNATIONAL (2020)
Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
Jose Luis Gorriz et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Role of sodium-glucose cotransporter 2 inhibition to mitigate diabetic kidney disease risk in type 1 diabetes
Daniel H. van Raalte et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial
Hiddo J. L. Heerspink et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition
Nitin A. Das et al.
CELLULAR SIGNALLING (2020)
SGLT2 Inhibitor Empagliflozin and DPP4 Inhibitor Linagliptin Reactivate Glomerular Autophagy in db/db Mice, a Model of Type 2 Diabetes
Anton I. Korbut et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease
Kazuomi Kario et al.
PROGRESS IN CARDIOVASCULAR DISEASES (2020)
Improvement in glycaemic parameters using SGLT-2 inhibitor and GLP-1 agonist in combination in an adolescent with diabetes mellitus and Prader-Willi syndrome: a case report
Toby Candler et al.
JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM (2020)
Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis A Multicenter Cohort Study
Antonios Douros et al.
ANNALS OF INTERNAL MEDICINE (2020)
Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF
Alice M. Jackson et al.
CIRCULATION (2020)
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease
Claudio Borghi et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2020)
SGLT2i: beyond the glucose-lowering effect
Lihua Ni et al.
CARDIOVASCULAR DIABETOLOGY (2020)
Dapagliflozin Activates Neurons in the Central Nervous System and Regulates Cardiovascular Activity by Inhibiting SGLT-2 in Mice
Thiquynhnga Nguyen et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2020)
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
Milton Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J. L. Heerspink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A role for tubular Na+/H+ exchanger NHE3 in the natriuretic effect of the SGLT2 inhibitor empagliflozin
Akira Onishi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2020)
Osmotic diuresis by SGLT2 inhibition stimulates vasopressin-induced water reabsorption to maintain body fluid volume
Takahiro Masuda et al.
PHYSIOLOGICAL REPORTS (2020)
Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System
Tuba M. Ansary et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats
Rachel J. Perry et al.
NATURE COMMUNICATIONS (2019)
Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys
Sungjin Chung et al.
FRONTIERS IN PHYSIOLOGY (2019)
Tissue sodium content in patients with type 2 diabetes mellitus
Dennis Kannenkeril et al.
JOURNAL OF DIABETES AND ITS COMPLICATIONS (2019)
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
V. Perkovic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure
Andre J. Scheen
CURRENT CARDIOLOGY REPORTS (2019)
SGLT-2 inhibitors as promising therapeutics for non-alcoholic fatty liver disease: pathophysiology, clinical outcomes, and future directions
Naser Eddin Gharaibeh et al.
DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY (2019)
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
J. J. V. McMurray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats
Mamdouh A. Oraby et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet
Liang Xu et al.
BMJ OPEN DIABETES RESEARCH & CARE (2019)
Effects of Dapagliflozin on Circulating Markers of Phosphate Homeostasis
Maarten A. de Jong et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
S. D. Wiviott et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
Takayoshi Suga et al.
MOLECULAR METABOLISM (2019)
Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy
Ryan B. Dull et al.
JOURNAL OF PHARMACY PRACTICE (2019)
Prompt apoptotic response to high glucose in SGLT-expressing renal cells
Linnea M. Nilsson et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
Effect of renal tubule-specific knockdown of the Na+/H+ exchanger NHE3 in Akita diabetic mice
Akira Onishi et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2019)
Effect of a SGLT2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats
Lei Li et al.
JOURNAL OF PHARMACOLOGICAL SCIENCES (2018)
Weak bones in diabetes mellitus - an update on pharmaceutical treatment options
Daphne P. L. Lin et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2018)
Emerging roles of SGLT2 inhibitors in obesity and insulin resistance: Focus on fat browning and macrophage polarization
Liang Xu et al.
ADIPOCYTE (2018)
Review: In adults with type 1 diabetes, SGLT-2 inhibitors reduce HbA1c but increase diabetic ketoacidosis
Aoife M. Egan et al.
ANNALS OF INTERNAL MEDICINE (2018)
Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells
Chenke Xu et al.
BIOCHEMICAL PHARMACOLOGY (2018)
SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial
M. V. Karg et al.
CARDIOVASCULAR DIABETOLOGY (2018)
Independent regulation of renin-angiotensin-aldosterone system in the kidney
Akira Nishiyama et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2018)
Effects of SGLT2 Inhibitors on Renin-Aldosterone System for One Month and Six Months in Type 2 Diabetes
Ichiro Mori et al.
DIABETES (2018)
Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2
Chiara Ghezzi et al.
DIABETOLOGIA (2018)
Hypertension with diabetes mellitus complications
Daisuke Yamazaki et al.
HYPERTENSION RESEARCH (2018)
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
Motoaki Sano
JOURNAL OF CARDIOLOGY (2018)
EMPAGLIFLOZIN AND CANAGLIFLOZIN ATTENUATE INFLAMMATORY CYTOKINES INTERFERON-γ, TUMOR NECROSIS FACTOR-α, INTERLEUKIN-6: POSSIBLE MECHANISM OF DECREASING CARDIOVASCULAR RISK IN DIABETES MELLITUS
Stanley Andrew Tan et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2018)
Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts
R. Estruch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Dapagliflozin, a Sodium-Glucose Co-transporter-2 Inhibitor, Acutely Reduces Energy Expenditure in Brown Adipose Tissue via Neural Signals in Mice
Yumiko Chiba et al.
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN (2018)
High Basolateral Glucose Increases Sodium-Glucose Cotransporter 2 and Reduces Sirtuin-1 in Renal Tubules through Glucose Transporter-2 Detection
Hiroyuki Umino et al.
SCIENTIFIC REPORTS (2018)
Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects
Christopher S. Wilcox et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2018)
Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
Eugene Han et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Effects of SGLT2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease
F. Bonnet et al.
DIABETES & METABOLISM (2018)
A sodium-glucose cotransporter 2 inhibitor attenuates renal capillary injury and fibrosis by a vascular endothelial growth factor-dependent pathway after renal injury in mice
Yifan Zhang et al.
KIDNEY INTERNATIONAL (2018)
Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120
Wen-Chih Liu et al.
TOXINS (2018)
The Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Sympathetic Nervous Activity
Ningning Wan et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Salt, water and nephron: Mechanisms of action and link to hypertension and chronic kidney disease
Qi Qian
NEPHROLOGY (2018)
Canagliflozin reduces plasma uremic toxins and alters the intestinal microbiota composition in a chronic kidney disease mouse model
Eikan Mishima et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)
Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na+/H+ exchanger, lowering of cytosolic Na+ and vasodilation
Laween Uthman et al.
DIABETOLOGIA (2018)
Alterations of Renal Epithelial Glucose and Uric Acid Transporters in Fructose Induced Metabolic Syndrome
Hwee-Yeong Ng et al.
KIDNEY & BLOOD PRESSURE RESEARCH (2018)
Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts
Masashi Mizuno et al.
PHYSIOLOGICAL REPORTS (2018)
The Susceptibility Genes in Diabetic Nephropathy
Ling Wei et al.
KIDNEY DISEASES (2018)
Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease
David Leon Jimenez et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2018)
Why do SGLT2 inhibitors reduce heart failure hospitalization? A differential volume regulation hypothesis
Karen M. Hallow et al.
DIABETES OBESITY & METABOLISM (2018)
Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition
Volker Vallon et al.
DIABETOLOGIA (2017)
Mediterranean diet and risk of heart failure: results from the PREDIMED randomized controlled trial
Angeliki Papadaki et al.
EUROPEAN JOURNAL OF HEART FAILURE (2017)
Pharmacokinetic drug evaluation of saxagliptin plus dapagliflozin for the treatment of type 2 diabetes
Andre J. Scheen
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2017)
Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
Tsung-Ming Lee et al.
FREE RADICAL BIOLOGY AND MEDICINE (2017)
Salt Sensitivity of Angiogenesis Inhibition-Induced Blood Pressure Rise Role of Interstitial Sodium Accumulation?
Stephanie Lankhorst et al.
HYPERTENSION (2017)
Arterial pressure lability is improved by sodium-glucose cotransporter 2 inhibitor in streptozotocin-induced diabetic rats
Tomoko Yoshikawa et al.
HYPERTENSION RESEARCH (2017)
Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure
Asadur Rahman et al.
HYPERTENSION RESEARCH (2017)
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy SGLT2 PROTEIN INHIBITION DECREASES RENAL LIPID ACCUMULATION, INFLAMMATION, AND THE DEVELOPMENT OF NEPHROPATHY IN DIABETIC MICE
Xiaoxin X. Wang et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
Role of the sympathetic nervous system in regulation of the sodium glucose cotransporter 2
Vance B. Matthews et al.
JOURNAL OF HYPERTENSION (2017)
Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes
Takuo Yoshimoto et al.
JOURNAL OF INVESTIGATIVE MEDICINE (2017)
Changes in Urinary Angiotensinogen Associated with Deterioration of Kidney Function in Patients with Type 2 Diabetes Mellitus
Min Jin Lee et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2017)
The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus
Jens Jordan et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2017)
Skin Sodium Concentration Correlates with Left Ventricular Hypertrophy in CKD
Markus P. Schneider et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment
Lennart Tonneijck et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature
Kelly R. Burke et al.
PHARMACOTHERAPY (2017)
High glucose augments angiotensinogen in human renal proximal tubular cells through hepatocyte nuclear factor-5
Juan Wang et al.
PLOS ONE (2017)
Role of Vitamin D in Uremic Vascular Calcification
Yi-Chou Hou et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Responses of renal hemodynamics and tubular functions to acute sodium-glucose cotransporter 2 inhibitor administration in non-diabetic anesthetized rats
Tuba M. Ansary et al.
SCIENTIFIC REPORTS (2017)
Carbohydrate restriction ameliorates nephropathy by reducing oxidative stress and upregulating HIF-1α levels in type-1 diabetic rats
Pawan Krishan et al.
JOURNAL OF DIABETES AND METABOLIC DISORDERS (2017)
Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells
A. Solini et al.
DIABETES & METABOLISM (2017)
Factors Responsible for Obesity-Related Hypertension
Kyungjoon Lim et al.
CURRENT HYPERTENSION REPORTS (2017)
Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats
Ling Chen et al.
AMERICAN JOURNAL OF THE MEDICAL SCIENCES (2016)
Effects of diabetes drugs on the skeleton
Christian Meier et al.
BONE (2016)
Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome
Hiroaki Kusaka et al.
CARDIOVASCULAR DIABETOLOGY (2016)
Influence of Renal Function on the 52-Week Efficacy and Safety of the Sodium Glucose Cotransporter 2 Inhibitor Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus
Masakazu Haneda et al.
CLINICAL THERAPEUTICS (2016)
A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats
Yui Takeshige et al.
HYPERTENSION RESEARCH (2016)
Role of Oxidative Stress in Drug-Induced Kidney Injury
Keiko Hosohata
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin
John P. Bilezikian et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2016)
Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome
Asadur Rahman et al.
JOURNAL OF HYPERTENSION (2016)
Sirt1 and the Mitochondria
Bor Luen Tang
MOLECULES AND CELLS (2016)
Is it time to think about the sodium glucose co-transporter 2 sympathetically?
Rosemary H. Elliott et al.
NEPHROLOGY (2016)
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Christoph Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice
Yumiko Chiba et al.
PLOS ONE (2016)
Effect of Sodium-Glucose Co-Transporter 2 Inhibitor, Dapagliflozin, on Renal Renin-Angiotensin System in an Animal Model of Type 2 Diabetes
Seok Joon Shin et al.
PLOS ONE (2016)
Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice
Linda A. Gallo et al.
SCIENTIFIC REPORTS (2016)
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure
James W. Reed
VASCULAR HEALTH AND RISK MANAGEMENT (2016)
Uric acid as a modulator of glucose and lipid metabolism
William Gustavo Lima et al.
BIOCHIMIE (2015)
Glycated Hemoglobin Level and Risk of Hip Fracture in Older People with Type 2 Diabetes: A Competing Risk Analysis of Taiwan Diabetes Cohort Study
Chia-Ing Li et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
Caroline Bonner et al.
NATURE MEDICINE (2015)
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Insulin stimulates SGLT2-mediated tubular glucose absorption via oxidative stress generation
Nobutaka Nakamura et al.
DIABETOLOGY & METABOLIC SYNDROME (2015)
Metabolic syndrome: a sympathetic disease?
Markus Schlaich et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Acute SGLT inhibition normalizes O-2 tension in the renal cortex but causes hypoxia in the renal medulla in anaesthetized control and diabetic rats
Julie O'Neill et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2015)
Hypoxia signaling pathways: modulators of oxygen-related organelles
Miriam J. Schonenberger et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2015)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Bowen Lin et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus
David Z. I. Cherney et al.
CIRCULATION (2014)
Proximal Tubule Function and Response to Acidosis
Norman P. Curthoys et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ele Ferrannini et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis
William L. Baker et al.
JOURNAL OF THE AMERICAN SOCIETY OF HYPERTENSION (2014)
Functional Role of Glucose Metabolism, Osmotic Stress, and Sodium-Glucose Cotransporter Isoform-Mediated Transport on Na+/H+ Exchanger Isoform 3 Activity in the Renal Proximal Tubule
Thaissa Dantas Pessoa et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2014)
Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes
David Z. I. Cherney et al.
KIDNEY INTERNATIONAL (2014)
The Sodium-Glucose Co-Transporter 2 Inhibitor Empagliflozin Improves Diabetes-Induced Vascular Dysfunction in the Streptozotocin Diabetes Rat Model by Interfering with Oxidative Stress and Glucotoxicity
Matthias Oelze et al.
PLOS ONE (2014)
The SGLT2 inhibitor empagliflozin ameliorates early features of diabetic nephropathy in BTBR ob/ob type 2 diabetic mice with and without hypertension
Florian Gembardt et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2014)
Linking uric acid metabolism to diabetic complications
Akifumi Kushiyama et al.
WORLD JOURNAL OF DIABETES (2014)
Ectopic lipid accumulation: A potential cause for metabolic disturbances and a contributor to the alteration of kidney function
Fitsum Guebre-Egziabher et al.
BIOCHIMIE (2013)
Regulation of erythropoiesis by hypoxia-inducible factors
Volker H. Haase
BLOOD REVIEWS (2013)
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
H. J. Lambers Heerspink et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J-F Yale et al.
DIABETES OBESITY & METABOLISM (2013)
Aberrant Activation of the Intrarenal Renin-Angiotensin System in the Developing Kidneys of Type 2 Diabetic Rats
Y. -Y. Fan et al.
HORMONE AND METABOLIC RESEARCH (2013)
Knockout of Na-glucose transporter SGLT2 attenuates hyperglycemia and glomerular hyperfiltration but not kidney growth or injury in diabetes mellitus
Volker Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2013)
Renal Function in Diabetic Disease Models: The Tubular System in the Pathophysiology of the Diabetic Kidney
Volker Vallon et al.
ANNUAL REVIEW OF PHYSIOLOGY, VOL 74 (2012)
Recent advances in renal urate transport: characterization of candidate transporters indicated by genome-wide association studies
Naohiko Anzai et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2012)
Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin
O. Ljunggren et al.
DIABETES OBESITY & METABOLISM (2012)
Liver Angiotensinogen Is the Primary Source of Renal Angiotensin II
Taiji Matsusaka et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2012)
SIRT1 and SIRT3 deacetylate homologous substrates: AceCS1,2 and HMGCS1,2
Matthew D. Hirschey et al.
AGING-US (2011)
Glucose handling by the kidney
Amanda Mather et al.
KIDNEY INTERNATIONAL (2011)
Sirtuin-1 regulation of mammalian metabolism
Matthew P. Gillum et al.
TRENDS IN MOLECULAR MEDICINE (2011)
Different clinical outcomes for cardiovascular events and mortality in chronic kidney disease according to underlying renal disease: the Gonryo study
Masaaki Nakayama et al.
CLINICAL AND EXPERIMENTAL NEPHROLOGY (2010)
The 2009 Carl Ludwig Lecture: pathophysiology of the human sympathetic nervous system in cardiovascular diseases: the transition from mechanisms to medical management
Murray Esler
JOURNAL OF APPLIED PHYSIOLOGY (2010)
Uric acid transport and disease
Alexander So et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Cardiovascular and Renal Complications of Type 2 Diabetes in Obesity: Role of Sympathetic Nerve Activity and Insulin Resistance
Kazuko Masuo et al.
CURRENT DIABETES REVIEWS (2010)
Blood pressure control: salt gets under your skin
Paul J. Marvar et al.
NATURE MEDICINE (2009)
Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism
Agnes Machnik et al.
NATURE MEDICINE (2009)
Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy
Frederic Preitner et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Spontaneously reduced blood pressure load in the rat streptozotocin-induced diabetes model: potential pathogenetic relevance
Anil K. Bidani et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2007)
Glomerular hyperfiltration in type 1 diabetes mellitus results from primary changes in proximal tubular sodium handling without changes in volume expansion
G Vervoort et al.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION (2005)
Nutrient control of glucose homeostasis through a complex of PGC-1α and SIRT1
JT Rodgers et al.
NATURE (2005)
Effects of pathophysiological concentrations of albumin on NHE3 activity and cell proliferation in primary cultures of human proximal tubule cells
EM Lee et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2003)
Weight loss improves neurovascular and muscle metaboreflex control in obesity
IC Trombetta et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2003)
Hypovolemia and MSNA discharge patterns: assessing and interpreting sympathetic responses
DS Kimmerly et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2003)
Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension
H Kobori et al.
HYPERTENSION (2003)
Salt-sensitivity of proximal reabsorption alters macula densa salt and explains the paradoxical effect of dietary salt on glomerular filtration rate in diabetes mellitus
V Vallon et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2002)
Urinary excretion of angiotensinogen reflects intrarenal angiotensinogen production
H Kobori et al.
KIDNEY INTERNATIONAL (2002)
Role of Na(+)/H(+) exchanger NHE3 in nephron function: micropuncture studies with S3226, an inhibitor of NHE3
V Vallon et al.
AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY (2000)
Share Paper
